Reports

As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Idiopathic Pulmonary Fibrosis Treatment Market: By Drug Class: Pirfenidone, Nintedanib; Regional Analysis; Historical Market and Forecast (2016-2026); SWOT Analysis; Porter’s Five Forces Analysis; EMR’s Key indicators for Demand, EMR’s Key Indicator for Price; Competitive Landscape; Industry Events and Developments

Global Idiopathic Pulmonary Fibrosis Treatment Market Outlook

The global idiopathic pulmonary fibrosis treatment market stood at USD 2.2 billion in 2020. The idiopathic pulmonary fibrosis treatment market is expected to grow at a CAGR of about 12% in the forecast period of 2021-2026, driven by the growing cases of lung diseases.

 

The industry is expected to attain a value of USD 4.3 billion by 2026. The market is being dominated by the North America and European regions.

 

Global Idiopathic Pulmonary Fibrosis Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Properties and Applications

Idiopathic pulmonary fibrosis (IPF) refers to a severe lung disease. As you breathe in, oxygen travels through tiny airbags in your lungs and into your bloodstream. This flows to the organs from there. IPF causes scar tissue to develop within the lungs, making it hard to breathe. The treatment of this disease can help in slowing down the damage to the lungs.

 

Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The idiopathic pulmonary fibrosis treatment market can be broadly categorised based on drug class into:

  • Pirfenidone
  • Nintedanib

The EMR report looks into the regional markets for idiopathic pulmonary fibrosis like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Global Idiopathic Pulmonary Fibrosis Treatment Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The increased prevalence of idiopathic pulmonary fibrosis (IPF) and the increasing geriatric population are the key drivers of the market. The increase in the number of people smoking cigarettes, leading to a high prevalence of IPF, is also projected to fuel the growth of the market.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Biogen, Inc. [BIIB (NASDAQ)]
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • F. Hoffmann-La Roche Ag 
  • Fibrogen, Inc. 
  • Galapagos Nv.
  • Medicinova, Inc. 
  • Merck & Co., Inc. 
  • Prometic Life Sciences Inc. 
  • Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key findings of the Study
2    Research Methodology
    2.1    Data Extraction
    2.2    Data Corroboration
    2.3    Market Structure
    2.4    Inference Data 
3    Executive Summary
    3.1    Market Overview
    3.2    Market Analysis
    3.3    Cost Structure
4    Global Idiopathic Pulmonary Fibrosis Treatment Market Analysis
    4.1    Global Idiopathic Pulmonary Fibrosis Treatment Historical Market (2016-2020) & Forecast (2021-2026)
    4.2    Global Idiopathic Pulmonary Fibrosis Treatment Market Breakup by Drug Class
        4.2.1    Pirfenidone
        4.2.2    Nintedanib
    4.3    Global Idiopathic Pulmonary Fibrosis Treatment Market Breakup by Drug Class: Historical Market (2016-2020) & Forecast (2021-2026)
        4.3.1    Pirfenidone
        4.3.2    Nintedanib
    4.4    Global Idiopathic Pulmonary Fibrosis Treatment Market Breakup by Region
        4.4.1    North America 
            4.4.1.1    United States of America
            4.4.1.2     Canada
        4.4.2    Europe 
            4.4.2.1    Germany
            4.4.2.2    United Kingdom
            4.4.2.3    France
            4.4.2.4    Italy
            4.4.2.5    Others
        4.4.3    Asia Pacific
            4.4.3.1    China
            4.4.3.2    Japan
            4.4.3.3    India
            4.4.3.4    ASEAN
            4.4.3.5    Others
        4.4.4    Latin America 
            4.4.4.1    Brazil    
            4.4.4.2    Argentina
            4.4.4.3    Mexico
            4.4.4.4    Others
        4.4.5    Middle East & Africa 
            4.4.5.1    Saudi Arabia  
            4.4.5.2    United Arab Emirates
            4.4.5.3    Nigeria
            4.4.5.4    South Africa
            4.4.5.5    Others
    4.5     Global Idiopathic Pulmonary Fibrosis Treatment Market Breakup by Region: Historical Market (2016-2020) & Forecast (2021-2026)
        4.5.1    North America 
            4.5.1.1    United States of America
            4.5.1.2     Canada
        4.5.2    Europe 
            4.5.2.1    Germany
            4.5.2.2    United Kingdom
            4.5.2.3    France
            4.5.2.4    Italy
            4.5.2.5    Others
        4.5.3    Asia Pacific
            4.5.3.1    China
            4.5.3.2    Japan
            4.5.3.3    India
            4.5.3.4    ASEAN
            4.5.3.5    Others
        4.5.4    Latin America 
            4.5.4.1    Brazil    
            4.5.4.2    Argentina
            4.5.4.3    Mexico
            4.5.4.4    Others
        4.5.5    Middle East & Africa 
            4.5.5.1    Saudi Arabia  
            4.5.5.2    United Arab Emirates
            4.5.5.3    Nigeria
            4.5.5.4    South Africa
            4.5.5.5    Others
5    SWOT Analysis
    5.1    Overview
    5.2    Strengths
    5.3    Weaknesses
    5.4    Opportunities
    5.5    Threats
6    Porter’s Five Forces Analysis
    6.1    Overview
    6.2    Buyer’s Power
    6.3    Supplier’s Power
    6.4    New Entrants
    6.5    Degree of Rivalry
    6.6    Substitutes
7    EMR’s Key indicators for Demand
8    EMR’s Key Indicator for Price

9    Key Players & Company Profiles
    9.1    Biogen, Inc. [BIIB (NASDAQ)]
        9.1.1    Company Overview
        9.1.2    Financial Analysis
    9.2    Boehringer Ingelheim
        9.2.1    Company Overview
        9.2.2    Financial Analysis
    9.3    Bristol-Myers Squibb Company
        9.3.1    Company Overview
        9.3.2    Financial Analysis
    9.4    Cipla Inc.
        9.4.1    Company Overview
        9.4.2    Financial Analysis
    9.5    F. Hoffmann-La Roche Ag [ROG (SWX)]
        9.5.1    Company Overview
        9.5.2    Financial Analysis
    9.6    Fibrogen, Inc. [FGEN (NASDAQ)]
        9.6.1    Company Overview
        9.6.2    Financial Analysis
    9.7    Galapagos Nv.
        9.7.1    Company Overview
        9.7.2    Financial Analysis
    9.8    Medicinova, Inc. [MNOV (NASDAQ)]
        9.8.1    Company Overview
        9.8.2    Financial Analysis
    9.9    Merck & Co., Inc. [MRK (NYSE)]
        9.9.1    Company Overview
        9.9.2    Financial Analysis
    9.10    Prometic Life Sciences Inc. [LMNL (TSE)]
        9.10.1    Company Overview
        9.10.2    Financial Analysis
    9.11    Others
10    Industry Events and Developments

Key Questions Answered in the Report

In 2020, the global idiopathic pulmonary fibrosis treatment market attained a value of nearly USD 2.2 billion.

The market is estimated to witness a healthy growth, expanding at a CAGR of 12% in the forecast period of 2021-2026.

The major drivers of the market include the growing cases of lung diseases, increasing geriatric population, and rising patient awareness, which is likely to propel the demand for idiopathic pulmonary fibrosis treatment.

The increasing number of smokers, which is leading to a rise in prevalence of IPF (idiopathic pulmonary fibrosis), is expected to be a key trend guiding the growth of the industry.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Pirfenidone and nintedanib are the different drug-classes of the treatment.

The major players in the industry are Biogen, Inc, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ag, Fibrogen, Inc., Galapagos Nv., Medicinova, Inc., Merck & Co., Inc., and Prometic Life Sciences Inc., among others.

Analyst Review

The global idiopathic pulmonary fibrosis treatment market attained a value of USD 2.2 billion in 2020, driven by the growing cases of lung diseases and increasing geriatric population. Aided by the growing prevalence of IPF (idiopathic pulmonary fibrosis) and advancements in the medical sector, the market is expected to witness a further growth in the forecast period of 2021-2026, growing at a CAGR of 12%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on drug-class, the market is divided into pirfenidone and nintedanib. The major regional markets for idiopathic pulmonary fibrosis treatment are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Biogen, Inc, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ag, Fibrogen, Inc., Galapagos Nv., Medicinova, Inc., Merck & Co., Inc., and Prometic Life Sciences Inc., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 1999     $1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 3199     $2499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$ 4199     $3499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 5199     $4499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports

Global Oxygen Therapy Market Report and Forecast 2021-2026


Global Topical Pain Relief Market Report and Forecast 2021-2026


Global Aortic Valve Replacement Market Report and Forecast 2021-2026


Global Radiation Oncology Market Report and Forecast 2021-2026


Global Noninvasive Neuromodulation Market Report and Forecast 2021-2026


NEWSLETTER